Skip to content

G&A at other companies

Regenxbio logo
RegenxbioRGNX
$21.31M+4.7%
Sana Biotechnology logo
Sana BiotechnologySANA
$11.46M-0.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$17.18M-11.0%
Guardant Health logo
Guardant HealthGH
$57.93M+23.4%

Segments

By segment

See full
Reportable Segment$12.72M

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's G&A?
Ginkgo Bioworks (DNA) reported G&A of $37.83M in Q1 2026.
How has Ginkgo Bioworks's G&A changed year-over-year?
Ginkgo Bioworks's G&A decreased by 4.8% year-over-year, from $39.72M to $37.83M.
What is the long-term trend for Ginkgo Bioworks's G&A?
Over 4 years (2021 to 2025), Ginkgo Bioworks's G&A has grown at a -33.0% compound annual growth rate (CAGR), from $862.95M to $173.97M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.